Clinical Report: FDA Approves Expanded Liquid Biopsy Panel
Overview
The FDA has approved the Guardant360 Liquid CDx, a comprehensive blood-based molecular profiling assay for advanced cancer treatment selection. This updated assay offers a broader genomic footprint and improved sensitivity for circulating tumor DNA detection.
Background
Liquid biopsies are increasingly important in oncology for their ability to provide rapid and comprehensive genomic insights from blood samples. The approval of the Guardant360 Liquid CDx represents a significant advancement in precision oncology, allowing for better treatment selection and monitoring in patients with advanced cancers. This assay's broad application across various cancer types underscores the growing reliance on non-invasive testing methods in clinical practice.
Data Highlights
The Guardant360 Liquid CDx assay is the largest FDA-approved liquid biopsy panel, with a genomic footprint 100 times broader than its predecessor. It retains seven FDA-approved companion diagnostic indications and is covered by Medicare and commercial insurers for over 300 million lives.
Key Findings
- The Guardant360 Liquid CDx assay combines genomic and epigenomic profiling from a single blood draw.
- It improves the sensitivity of circulating tumor DNA detection compared to the previous version.
- The assay can provide results within 7 days, facilitating timely treatment decisions.
- It is the only FDA-approved liquid biopsy companion diagnostic for targeted therapy selection in advanced breast cancer with ESR1 mutations.
- The platform is designed for use across multiple stages of cancer care, including treatment selection and recurrence monitoring.
Clinical Implications
Clinicians can utilize the Guardant360 Liquid CDx to make informed treatment decisions based on comprehensive molecular profiling without the need for tissue samples. The rapid turnaround time enhances the ability to initiate timely therapies, particularly in advanced cancer settings.
Conclusion
The approval of the Guardant360 Liquid CDx marks a pivotal step in enhancing precision oncology through advanced liquid biopsy technology, ultimately improving patient outcomes in cancer care.
Related Resources & Content
- Guardant Health, Press Release, 2026 -- FDA Approves Expanded Liquid Biopsy Panel
- Franklin / MDSpire, The Pathologist, 2026 -- Liquid Biopsy Demonstrates Clinical Utility Across GI Cancers, NSCLC, and Colorectal Cancer Treatment Guidance
- The Pathologist, 2026 -- Liquid Biopsy Supports Precision Oncology
- The Pathologist, 2026 -- Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting
- Franklin / MDSpire — Liquid Biopsy Demonstrates Clinical Utility Across GI Cancers, NSCLC, and Colorectal Cancer Treatment Guidance
- The ASCO Post — FDA Pipeline: Approval for First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic; Designations in Ovarian Cancer, Leukemia, and Lymphoma
- FDA Premarket Approval for Guardant360 Liquid CDx
- NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025
- FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation | FDA
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
